Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics
Authors:
Open Access
- 24 December 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8, 802989
Abstract
Background: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, outside of registries. The claims data from the French National Health System (SNDS) were used to describe outcomes in patients diagnosed with IPF in 2015–2016 but who did not receive antifibrotic therapies.Method: Patients aged Results: A total of 5,360 patients (43.2%) not treated with antifibrotic therapies were included. The mean age was 75.5 years, and 57.9% were males. In the year before inclusion, 47.3% of patients had a Charlson score ≥5. During follow-up, 41.2% of patients died. The unadjusted incidence rate was 29.9 per 100 person-years (95%CI = [28.7–31.2]), and the cumulative incidence of death at 3 years was 50.2% (95% CI = [48.3–52.1%]). In the study population, 35.3% of patients experienced an acute respiratory-related hospitalization. The unadjusted incidence rate was 32.1 per 100 person-years (95%CI = [30.6–33.5]) and the cumulative incidence of the event at 3 years was 41.5% (95% CI = [39.7–43.2%]).Interpretation: This observational study showed that, if untreated with antifibrotics, IPF is associated with a 50% all-cause mortality at 3 years. These figures can serve as a historical control of the natural course of the disease.Keywords
Funding Information
- F. Hoffmann-La Roche
This publication has 17 references indexed in Scilit:
- Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in FranceRevue D'Épidémiologie Et de Santé Publique, 2017
- Unmet needs in the treatment of idiopathic pulmonary fibrosis―insights from patient chart review in five European countriesBMC Pulmonary Medicine, 2017
- Idiopathic pulmonary fibrosisThe Lancet, 2017
- Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up StudyPLOS ONE, 2017
- Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosisThe Lancet Respiratory Medicine, 2017
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Management of idiopathic pulmonary fibrosis in France: A survey of 1244 pulmonologistsRespiratory Medicine, 2014
- Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical TrialsAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- Clinical Course and Prediction of Survival in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011